|By PR Newswire||
|February 12, 2014 09:43 AM EST||
NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
"PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012" report provides an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships.
The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top five deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.
Key Questions Answered
- How are the main deal categories faring among top countries in the Latin America region over the past five years?
- What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in LATAM region?
- What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Latin American region?
- What strategies are the most successful companies pursuing to gain and maintain their market leading position?
- Which are the key companies that are potential targets of acquisitions?
- Report provides in-depth understanding of the key pharmaceutical and healthcare deals that took place in the LATAM region during the past five years. Furthermore, key deals are discussed from a domestic and global point of view.
- Current regulatory framework in various markets in LATAM including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed. In-depth commentary on four countries in the region are included.
- Highly Insightful analyses on the deal making terms, strategic implications and synergies of recent deals activity in the LATAM pharmaceutical industry.
- Collaboration & Acquisition Strategies: Exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities. Case Studies of five deals are included in each deal category.
- Expert Insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place.
- Five major regional companies are profiled providing an in-depth analysis on their individual deal making strategies.
- Number of Case Studies on top deal making activities shedding light on rationale and strategy. Potential targets for acquisitions in the region are also identified.
Reasons to buy
- Understand the primary drivers behind major deal initiatives in the LATAM region.
- Analyze the structure of the deals and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
- Use this information as an independent source for your due diligence and transaction strategy.
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Report Scope 14
2.1.1 Key Questions Answered 14
2.1.2 Key Benefits 15
2.1.3 Upcoming Related Reports 15
3 Historical Dealmaking Trends 16
3.1 Overview 16
3.2 Leading Deal Drivers 17
3.2.1 Dampening Global Pharmaceutical Markets 17
3.2.2 Intellectual Property Issues and Rising Competition 18
3.2.3 Universal Healthcare Access, Primary Healthcare, and Health Insurance 19
3.2.4 Increasing Consolidation 20
3.3 Overall Deals in Review 21
3.3.1 Review by Deal Type 21
4 Regional Country Profiles 28
4.1 Brazil 28
4.1.1 Overview 28
4.1.2 Top Deals by Value and Volume 29
4.1.3 Market Dynamics 31
4.2 Mexico 34
4.2.1 Overview 34
4.2.2 Top Deals by Value and Volume 35
4.2.3 Market Dynamics 37
4.3 Argentina 41
4.3.1 Overview 41
4.3.2 Top Deals by Value and Volume 42
4.3.3 Market Dynamics 44
4.4 Venezuela 48
4.4.1 Overview 48
4.4.2 Top Deals by Value and Volume 49
4.4.3 Market Dynamics 51
5 Mergers and Acquisitions 55
5.1 Overview 55
5.2 Case Studies 57
5.2.1 UnitedHealth Group Acquires Amil Participações 57
5.2.2 Hypermarcas Acquires Mantecorp Indústria Química e Farmacêutica 59
5.2.3 Hypermarcas Acquires Laboratório Neo Química 60
5.2.4 Acquisition of Lafrancol (Colombia) by Recalcine (Chile) 61
5.2.5 Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
6 Licensing Agreements 64
6.1 Overview 64
6.2 Case Studies 66
6.2.1 FBM Indústria Farmacêutica (FBM Farma) Enters into Licensing Agreement with Ampio Pharmaceuticals 66
6.2.2 FAES Farma and Pfizer Expand Bilastine License Agreement 67
6.2.3 CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
6.2.4 Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
6.2.5 Oxford Nutrascience Enters into Licensing Agreement with Aché Laboratórios 71
7 Collaborations and Partnerships 73
7.1 Overview 73
7.2 Case Studies 75
7.2.1 Pfizer Enters into an Agreement with Laboratório Teuto Brasileiro 75
7.2.2 Avesthagen Forms a Joint Venture with Uxmal 77
7.2.3 Baxter International Enters into Agreement with Hemobras for Recombinant Factor VIII (rFVIII) Hemophilia Treatment 78
7.2.4 Cristalia, Biolab, Eurofarma, and Libbs Enter into Joint Venture for Biological Medicines 80
7.2.5 Aché , Uniao Química Farmacêutica, Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
8 Deal Strategy of Major LATAM Companies 83
8.1 Amil Participações S.A. 83
8.1.1 Recent Deals: M&As, Licensing, and Partnerships 83
8.1.2 Overall Deal Strategy 84
8.2 Hypermarcas 85
8.2.1 Recent Deals: M&As, Licensing, and Partnerships 85
8.2.2 Overall Deals Strategy 86
8.3 Grupo Casa Saba 87
8.3.1 Recent Deals: M&As, Licensing, and Partnerships 87
8.3.2 Overall Deals Strategy 87
8.4 Genomma Lab Internacional 88
8.4.1 Recent Deals: M&As, Licensing, and Partnerships 88
8.4.2 Overall Deals Strategy 88
8.5 CFR Pharmaceuticals 89
8.5.1 Recent Deals: M&As, Licensing, and Partnerships 89
8.5.2 Overall Deals Strategy 90
9 Future Outlook 91
9.1 Overview 91
9.2 Deal-Making Trends 91
9.2.1 Mergers and Acquisitions 91
9.2.2 Licensing and Partnership Deals to Rise in Quest for Portfolio and Pipeline Growth 93
9.2.3 Market Access Challenges will Impact Deal Activity 93
10 Appendix 95
10.1 Bibliography 95
10.2 Abbreviations 97
10.3 About the Author 100
10.3.1 Industry Analyst 100
10.4 Director of Healthcare Industry Dynamics 100
10.5 Global Head of Healthcare 101
10.6 About the Industry Dynamics Team 101
10.7 About GlobalData 101
10.8 Disclaimer 102
1.1 List of Tables
Table 1: Overview of Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Brazil, 2008-2012 29
Table 2: Market Share Split of Pharma Firms in Brazil 33
Table 3: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Mexico, 2008-2012 35
Table 4: Pharmaceutical Market, Mexico, Forecast ($bn), 2011-2020 38
Table 5: Top 10 Pharma Firms in Mexico Revenue-Wise 39
Table 6: Top Healthcare Distribution Firms in Mexico Revenue-Wise 40
Table 7: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Argentina, 2008-2012 42
Table 8: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Table 9: Top 10 Pharma Firms in Argentina, Revenue-Wise 46
Table 10: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Venezuela, 2008-2012 49
Table 11: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Table 12: Top 10 M&A Deals by Value, LATAM Region, 2008-2012 56
Table 13: UnitedHealth Acquires Amil Participações 57
Table 14: Hypermarcas Acquires Mantecorp 59
Table 15: Hypermarcas Acquires Laboratório Neo Química Comércio e Indústria 60
Table 16: Recalcine Acquires Lafrancol 61
Table 17: Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
Table 18: Major Licensing Deals, LATAM Region, 2008-2012 64
Table 19: FBM Farma Indústria Farmacêutica Licenses Zertane from Ampio Pharmaceuticals 66
Table 20: Pfizer and Faes Farma in Licensing Deal for Bilastine 67
Table 21: CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
Table 22: Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
Table 23: Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratórios 71
Table 24: Top 10 Collaboration and Partnership Deals in the LATAM Region, 2008-2012 74
Table 25: Pfizer Enters Into An Agreement With Laboratório Teuto Brasileiro 75
Table 26: Avesthagen Enters into Agreement with Uxmal 77
Table 27: Baxter International Enters Into Agreement With Hemobras 78
Table 28: Cristalia, Biolab, Eurofarma and Libbs Enter into Joint Venture 80
Table 29: Aché , Uniao Química Farmacêutica , Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
Table 30: Amil Participações ' Recent Deals Activity 83
Table 31: Hypermarcas' Recent Deals Activity 85
Table 32: Grupo Casa Saba's Recent Deals Activity 87
Table 33: Genomma Lab Internacional's Recent Deals Activity 88
Table 34: CFR Pharmaceuticals' Recent Deals Activity 89
List of Figures
Figure 1: Foreign Direct Investment Flow, LATAM Region, 2011-2012 17
Figure 2: Research and Development Spending of PhRMA Members, 2005-2012 18
Figure 3: Trend in M&A Deal Volume, LATAM Region, 2008-2012 22
Figure 4: Trend in M&A Deal Values, LATAM Region, 2008-2012 23
Figure 5: Volume of Licensing Deals, LATAM Region, 2008-2012 24
Figure 6: Trend in Licensing Deal Values, LATAM Region, 2008-2012 25
Figure 7: Trend in Collaboration and Partnership Deal Volumes, LATAM Region, 2009-2012 26
Figure 8: Trend in Collaboration and Partnership Deal Values, LATAM Region, 2009-2012 27
Figure 9: Trends in Deal Volume in Brazil, 2008-2012 30
Figure 10: Volume of Deal Types in Brazil, 2008-2012 31
Figure 11: Pharmaceutical Market, Brazil, Revenue ($bn), Forecast, 2013-2020 32
Figure 12: Trends in Deal Volume in Mexico, 2008-2012 36
Figure 13: Volume of Deal Types in Mexico, 2008-2012 37
Figure 14: Trend in Market Forecast in Mexico, 2011-2020 38
Figure 15: Trends in Deal Volume in Argentina, 2008-2012 43
Figure 16: Volume of Deal Types in Argentina, 2008-2012 44
Figure 17: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Figure 18: Trends in Deal Volume in Venezuela, 2009-2012 50
Figure 19: Trends in Volume of Deal Types in Venezuela, 2009-2012 50
Figure 20: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Figure 21: Number of M&A Deals in Major Countries, LATAM Region, 2008-2012 57
Figure 22: Split in Volume of Licensing Deals among Drug Development Phases, LATAM Region, 2008-2012 65
To order this report: PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
Contact Clare: [email protected]
Intl: +1 339-368-6001
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. ...
Jul. 2, 2015 04:15 PM EDT Reads: 1,041
"We help to transform an organization and their operations and make them more efficient, more agile, and more nimble to move into the cloud or to move between cloud providers and create an agnostic tool set," noted Jeremy Steinert, DevOps Services Practice Lead at WSM International, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 2, 2015 04:13 PM EDT Reads: 593
The basic integration architecture, as defined by ESBs, hasn’t changed for more than a decade. Most cloud integration providers still rely on an ESB architecture and their proprietary connectors. As a result, enterprise integration projects suffer from constraints of availability and reliability of these connectors that are not re-usable across other integration vendors. However, the rapid adoption of APIs and almost ubiquitous availability of APIs amongst most SaaS and Cloud applications are ra...
Jul. 2, 2015 03:18 PM EDT Reads: 670
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
Jul. 2, 2015 03:00 PM EDT Reads: 1,029
"What Dyn is able to do with our Internet performance and our Internet intelligence is give companies visibility into what is actually going on in that cloud," noted Corey Hamilton, Product Marketing Manager at Dyn, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 2, 2015 02:52 PM EDT Reads: 653
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
Jul. 2, 2015 02:30 PM EDT Reads: 1,221
Internet of Things is moving from being a hype to a reality. Experts estimate that internet connected cars will grow to 152 million, while over 100 million internet connected wireless light bulbs and lamps will be operational by 2020. These and many other intriguing statistics highlight the importance of Internet powered devices and how market penetration is going to multiply many times over in the next few years.
Jul. 2, 2015 02:15 PM EDT Reads: 2,223
Manufacturing has widely adopted standardized and automated processes to create designs, build them, and maintain them through their life cycle. However, many modern manufacturing systems go beyond mechanized workflows to introduce empowered workers, flexible collaboration, and rapid iteration. Such behaviors also characterize open source software development and are at the heart of DevOps culture, processes, and tooling.
Jul. 2, 2015 02:15 PM EDT Reads: 899
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, will explore the IoT cloud-based platform technologies drivi...
Jul. 2, 2015 02:00 PM EDT Reads: 1,077
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of...
Jul. 2, 2015 01:45 PM EDT Reads: 2,324
Live Webinar with 451 Research Analyst Peter Christy. Join us on Wednesday July 22, 2015, at 10 am PT / 1 pm ET In a world where users are on the Internet and the applications are in the cloud, how do you maintain your historic SLA with your users? Peter Christy, Research Director, Networks at 451 Research, will discuss this new network paradigm, one in which there is no LAN and no WAN, and discuss what users and network administrators gain and give up when migrating to the agile world of clo...
Jul. 2, 2015 01:36 PM EDT Reads: 639
SYS-CON Events announced today that JFrog, maker of Artifactory, the popular Binary Repository Manager, will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based in California, Israel and France, founded by longtime field-experts, JFrog, creator of Artifactory and Bintray, has provided the market with the first Binary Repository solution and a software distribution social platform.
Jul. 2, 2015 01:00 PM EDT Reads: 1,271
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 2, 2015 01:00 PM EDT Reads: 1,067
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
Jul. 2, 2015 12:00 PM EDT Reads: 2,046
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult – let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and liv...
Jul. 2, 2015 11:50 AM EDT Reads: 590